Seamus Fernandez
Stock Analyst at Guggenheim
(3.75)
# 576
Out of 4,784 analysts
98
Total ratings
50%
Success rate
8.13%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERV Verve Therapeutics | Reiterates: Buy | n/a | $5.22 | - | 2 | Mar 25, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $69.46 | +130.35% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $28.00 | +100.00% | 1 | Feb 25, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $15.73 | - | 2 | Feb 24, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | n/a | $14.66 | - | 2 | Feb 24, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $39.72 | - | 7 | Feb 10, 2025 | |
| CDTX Cidara Therapeutics | Initiates: Buy | $33 | $22.39 | +47.39% | 1 | Nov 8, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $89.23 | +45.69% | 13 | Nov 6, 2024 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $38.74 | - | 2 | Oct 31, 2024 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Buy | $70 | $54.80 | +27.74% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $6.49 | +146.53% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $44 | $7.76 | +467.01% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $884 → $1,030 | $822.51 | +25.23% | 14 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.59 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.32 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $11.58 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $19.77 | +152.91% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $60.02 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $69.30 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $112.57 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.11 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $131.81 | -79.52% | 4 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.59 | +3,296.23% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $19.93 | +125.79% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $73.79 | -48.50% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $25.21 | +50.73% | 3 | Jan 31, 2018 |
Verve Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: n/a
Current: $5.22
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $69.46
Upside: +130.35%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $28.00
Upside: +100.00%
Arcutis Biotherapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $15.73
Upside: -
Mineralys Therapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $14.66
Upside: -
Apogee Therapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $39.72
Upside: -
Cidara Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $33
Current: $22.39
Upside: +47.39%
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $89.23
Upside: +45.69%
GSK plc
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $38.74
Upside: -
Rhythm Pharmaceuticals
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $54.80
Upside: +27.74%
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $6.49
Upside: +146.53%
Oct 8, 2024
Initiates: Buy
Price Target: $44
Current: $7.76
Upside: +467.01%
Aug 16, 2024
Maintains: Buy
Price Target: $884 → $1,030
Current: $822.51
Upside: +25.23%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.32
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $11.58
Upside: -
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $19.77
Upside: +152.91%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $60.02
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $69.30
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $112.57
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.11
Upside: -
Nov 15, 2018
Initiates: Outperform
Price Target: $27
Current: $131.81
Upside: -79.52%
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.59
Upside: +3,296.23%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $19.93
Upside: +125.79%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $73.79
Upside: -48.50%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $25.21
Upside: +50.73%